MEK1/2 inhibitors block basal and transforming growth factor 1beta1-stimulated JC virus multiplication

Veerasamy Ravichandran1, Peter N Jensen, Eugene O Major

  • 1Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1296, USA.

Journal of Virology
|April 6, 2007
PubMed

Insights

Activating the MEK1 pathway significantly boosts JC virus (JCV) replication in human glial cells. Inhibiting MEK1/2 effectively blocks JCV multiplication, suggesting a therapeutic target for JCV infections.

Area of Science:

  • Virology
  • Molecular Biology
  • Cell Signaling

Background:

  • JC virus (JCV) multiplication is influenced by cellular factors, including signaling pathways.
  • Understanding JCV's regulatory mechanisms is crucial for developing antiviral strategies.

Purpose of the Study:

  • To investigate the role of specific mitogen-activated protein kinase (MAPK) pathways in JC virus (JCV) replication.
  • To determine if transforming growth factor beta1 (TGF-beta1) impacts JCV infection through signaling cascades.

Main Methods:

  • Overexpression of constitutively active MEK1 (CA-MEK1) in human glial cells.
  • Assessing JCV late protein (Vp-1) synthesis following pathway activation or inhibition.
  • Utilizing MEK1/2 inhibitors (PD98059, U0126) and TGF-beta1 treatment.

Main Results:

  • Constitutively active MEK1 significantly increased JCV Vp-1 synthesis.
  • TGF-beta1 treatment stimulated a 200% increase in Vp-1 expression.
  • MEK1/2 inhibitors reduced basal and TGF-beta1-stimulated Vp-1 expression by over 95%.

Conclusions:

  • The MEK1 signaling pathway is a critical regulator of JC virus (JCV) multiplication.
  • MEK1/2 inhibitors demonstrate potent antiviral activity against JCV.
  • Targeting the MEK1/2 pathway offers a promising therapeutic avenue for JCV infections.

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...